ES2665917T3 - Endoxifeno para su uso en el tratamiento del cáncer - Google Patents
Endoxifeno para su uso en el tratamiento del cáncer Download PDFInfo
- Publication number
- ES2665917T3 ES2665917T3 ES07871563.8T ES07871563T ES2665917T3 ES 2665917 T3 ES2665917 T3 ES 2665917T3 ES 07871563 T ES07871563 T ES 07871563T ES 2665917 T3 ES2665917 T3 ES 2665917T3
- Authority
- ES
- Spain
- Prior art keywords
- endoxifene
- cancer treatment
- endoxyphene
- cancer
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/10—Oxygen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dispersion Chemistry (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Pyrane Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86042006P | 2006-11-21 | 2006-11-21 | |
| US860420P | 2006-11-21 | ||
| US86078806P | 2006-11-22 | 2006-11-22 | |
| US860788P | 2006-11-22 | ||
| PCT/US2007/085443 WO2008070463A2 (en) | 2006-11-21 | 2007-11-21 | Endoxifen methods and compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2665917T3 true ES2665917T3 (es) | 2018-04-30 |
Family
ID=39492975
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES07871563.8T Active ES2665917T3 (es) | 2006-11-21 | 2007-11-21 | Endoxifeno para su uso en el tratamiento del cáncer |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US9333190B2 (enExample) |
| EP (1) | EP2101731B1 (enExample) |
| JP (1) | JP2010510327A (enExample) |
| CA (1) | CA2669913C (enExample) |
| DK (1) | DK2101731T3 (enExample) |
| ES (1) | ES2665917T3 (enExample) |
| HU (1) | HUE037109T2 (enExample) |
| IN (1) | IN2014MN00139A (enExample) |
| PL (1) | PL2101731T3 (enExample) |
| PT (1) | PT2101731T (enExample) |
| WO (1) | WO2008070463A2 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010510327A (ja) | 2006-11-21 | 2010-04-02 | ジャイナ ファーマシューティカルズ，インコーポレーテッド | エンドキシフェンの方法および組成物 |
| US20090291134A1 (en) | 2006-11-21 | 2009-11-26 | Jina Pharmaceuticals, Inc. | Endoxifen methods and compositions in the treatment of psychiatric and neurodegenerative diseases |
| DK3202420T3 (da) * | 2008-12-11 | 2020-04-06 | Besins Healthcare Lu Sarl | Transdermale farmaceutiske sammensætninger omfattende en serm |
| HUE060783T2 (hu) | 2011-04-28 | 2023-04-28 | Oncopeptides Ab | Citotoxikus dipeptidek liofilizált készítménye |
| EP2668945A1 (de) | 2012-06-01 | 2013-12-04 | Bayer Technology Services GmbH | Genotyp- bzw. Phänotyp-basierte Arzeimittelformulierungen |
| KR102205592B1 (ko) * | 2012-10-26 | 2021-01-20 | 온코펩타이드즈 아베 | 멜팔란 플루펜아미드의 동결건조 제제 |
| EP3322406A4 (en) * | 2015-07-14 | 2019-06-12 | Atossa Genetics Inc. | TRANSPAPILLARY METHOD AND COMPOSITION FOR THE TREATMENT OF BREAST DISEASES |
| DE102015222031A1 (de) | 2015-11-10 | 2017-05-11 | Robert Bosch Gesellschaft Für Medizinische Forschung Mbh | Synthese von (Z)-Endoxifenhydrochlorid |
| US20170304232A1 (en) * | 2016-04-20 | 2017-10-26 | Northwestern University | Endoxifen For Local Transdermal Therapy To The Breast |
| KR20200052349A (ko) | 2017-09-11 | 2020-05-14 | 아토사 테라퓨틱스, 인크. | 엔독시펜을 제조 및 사용하는 방법 |
| CN111212631A (zh) * | 2017-09-11 | 2020-05-29 | 阿托莎医疗公司 | 局部用组合物和治疗方法 |
| JP7662204B2 (ja) * | 2019-07-03 | 2025-04-15 | アトッサ・セラピューティクス・インコーポレイテッド | エンドキシフェンの徐放性組成物 |
| WO2021205402A1 (en) | 2020-04-10 | 2021-10-14 | Jina Pharmaceuticals, Inc. | Endoxifen for the treatment of bipolar i disorder |
| US12245997B2 (en) | 2020-04-10 | 2025-03-11 | Jina Pharmaceuticals, Inc. | Endoxifen for the treatment of bipolar I disorder |
| TW202302073A (zh) * | 2021-03-18 | 2023-01-16 | 予宇生技股份有限公司 | 包含帶電脂質的脂質製劑的組合物及製備方法 |
| TW202340135A (zh) | 2022-01-12 | 2023-10-16 | 美商阿托薩醫療公司 | （ｚ）—因多昔芬之組合物及其富集方法 |
| CN119300811A (zh) * | 2022-04-26 | 2025-01-10 | 阿托萨治疗学公司 | 高剂量因多昔芬制剂和使用方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2817157A1 (de) * | 1978-04-17 | 1979-10-25 | Schering Ag | Verwendung von antioestrogenen und antigonadotrop wirkenden antiandrogenen zur prophylaxe und therapie der prostatahyperplasie |
| SK283026B6 (sk) * | 1994-08-04 | 2003-02-04 | Quadrant Holdings Cambridge Limited | Tuhý časticový prostriedok na terapeutické použitie a spôsob jeho prípravy |
| US6290991B1 (en) * | 1994-12-02 | 2001-09-18 | Quandrant Holdings Cambridge Limited | Solid dose delivery vehicle and methods of making same |
| WO1997040679A1 (en) * | 1996-05-01 | 1997-11-06 | Imarx Pharmaceutical Corp. | Methods for delivering compounds into a cell |
| US6090407A (en) * | 1997-09-23 | 2000-07-18 | Research Development Foundation | Small particle liposome aerosols for delivery of anti-cancer drugs |
| US7968532B2 (en) | 2003-12-15 | 2011-06-28 | Besins Healthcare Luxembourg | Treatment of gynecomastia with 4-hydroxy tamoxifen |
| CA2666322C (en) | 2006-10-10 | 2013-04-23 | Jina Pharmaceuticals, Inc. | Aqueous systems for the preparation of lipid-based pharmaceutical compounds; compositions, methods, and uses thereof |
| WO2008048194A1 (en) | 2006-10-20 | 2008-04-24 | Yesilogluj Aysegul Yildiz | Use of the protein kinase c inhibitor tamoxifen for the treatment of bipolar disorder |
| CA2669355C (en) | 2006-11-06 | 2012-10-30 | Jina Pharmaceuticals, Inc. | Guggulphospholipid methods and compositions |
| US20090291134A1 (en) | 2006-11-21 | 2009-11-26 | Jina Pharmaceuticals, Inc. | Endoxifen methods and compositions in the treatment of psychiatric and neurodegenerative diseases |
| JP2010510327A (ja) | 2006-11-21 | 2010-04-02 | ジャイナ ファーマシューティカルズ，インコーポレーテッド | エンドキシフェンの方法および組成物 |
| JP5720881B2 (ja) | 2011-01-31 | 2015-05-20 | 東芝ライテック株式会社 | Ｌｅｄランプ点灯装置および照明装置 |
-
2007
- 2007-11-21 JP JP2009538518A patent/JP2010510327A/ja active Pending
- 2007-11-21 PL PL07871563T patent/PL2101731T3/pl unknown
- 2007-11-21 WO PCT/US2007/085443 patent/WO2008070463A2/en not_active Ceased
- 2007-11-21 US US12/515,261 patent/US9333190B2/en active Active
- 2007-11-21 EP EP07871563.8A patent/EP2101731B1/en not_active Revoked
- 2007-11-21 HU HUE07871563A patent/HUE037109T2/hu unknown
- 2007-11-21 DK DK07871563.8T patent/DK2101731T3/en active
- 2007-11-21 PT PT78715638T patent/PT2101731T/pt unknown
- 2007-11-21 CA CA2669913A patent/CA2669913C/en active Active
- 2007-11-21 IN IN139MUN2014 patent/IN2014MN00139A/en unknown
- 2007-11-21 ES ES07871563.8T patent/ES2665917T3/es active Active
-
2016
- 2016-04-27 US US15/139,687 patent/US10376479B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US9333190B2 (en) | 2016-05-10 |
| CA2669913A1 (en) | 2008-06-12 |
| US20100112041A1 (en) | 2010-05-06 |
| JP2010510327A (ja) | 2010-04-02 |
| WO2008070463A3 (en) | 2008-11-06 |
| DK2101731T3 (en) | 2018-04-16 |
| US20160346230A1 (en) | 2016-12-01 |
| US10376479B2 (en) | 2019-08-13 |
| EP2101731A4 (en) | 2011-04-20 |
| CA2669913C (en) | 2012-09-18 |
| WO2008070463A9 (en) | 2008-09-18 |
| EP2101731B1 (en) | 2018-01-31 |
| EP2101731A2 (en) | 2009-09-23 |
| IN2014MN00139A (enExample) | 2015-06-19 |
| PT2101731T (pt) | 2018-04-18 |
| WO2008070463A2 (en) | 2008-06-12 |
| PL2101731T3 (pl) | 2018-07-31 |
| HUE037109T2 (hu) | 2018-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2665917T3 (es) | Endoxifeno para su uso en el tratamiento del cáncer | |
| ES2502472T3 (es) | Composición adhesiva para su uso en un inmunosensor | |
| ES2629749T3 (es) | Inmunidad tumoral | |
| ES2496092T3 (es) | El uso de amisulprida para tratar náuseas y vómitos posoperatorios | |
| ES2575152T3 (es) | Combinación terapéutica y uso de anticuerpos antagonistas de DLL4 y agentes antihipertensores | |
| ES2649340T3 (es) | Administración de fármacos activados por hipoxia y agentes antiangiogénicos para el tratamiento del cáncer | |
| ES2483725T3 (es) | Composición básica cosmética y su uso | |
| CL2008001656A1 (es) | Anticuerpo anti-c3b; composicion farmaceutica que lo comprende, y su uso para prevenir o tratar un trastorno asociado con el complemento; kit que lo contiene. | |
| ES2602810T3 (es) | Composición mejorada | |
| ES2478820T3 (es) | Tratamiento de degeneración macular | |
| CL2008002369A1 (es) | Compuestos derivados de piridin-3-il-oxipiridin-2-il-amino, inhibidores de alk5; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento del cancer. | |
| CL2009000545A1 (es) | Uso de un antagonista de c-met y un antagonista de her para el tratamiento de cancer. | |
| ES2515168T3 (es) | Detección y tratamiento de la esquizofrenia | |
| CL2007003138A1 (es) | Compuestos derivados de anilinopiperazina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer. | |
| CL2008001024A1 (es) | Compuestos derivados de ftalazinona; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de enfermedades cardiovasculares, parkinson, enfermedades inflamatorias, esclerosis multiple, cancer, entre otras | |
| CL2010000188A1 (es) | Metodo para el tratamiento de una infeccion en un sujeto que comprende la administracion de 9-[(2,2-dimetil-propilamino)-metil]-minociclina o de una sal de la misma; composicion farmaceutica que comprende dicho compuesto; y su uso. | |
| ES2563777T3 (es) | Compuestos de nitrona para tratar la pérdida auditiva sensorineural | |
| ES2564172T3 (es) | Utilización de una composición cosmética para el cuidado de las pieles grasas | |
| ES2546198T3 (es) | Tratamiento contra la glomerulonefritis | |
| ES2531516T3 (es) | Uso de escina | |
| CL2007002380A1 (es) | Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento terapeutico y/o profilactico de la queratosis actinica. | |
| CR11859A (es) | Composición y proceso-356 | |
| CO6321285A2 (es) | Uso de 3,11b-cis- dihidrotetrabenazina en el tratamiento de la esclerosis multiple y la mielitis autoinmunitaria | |
| ES2629309T3 (es) | Formulaciones de tratamiento de la mucositis inducida por terapia antitumoral o inmunosupresora | |
| CL2008001990A1 (es) | Compuestos derivados de amino-quinazolinas sustituidas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de alzheimer. |